Jiangsu Hengrui Medicine Co Ltd Total Assets
Jiangsu Hengrui Medicine Co Ltd total assets. Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) holds total assets worth CN¥68.33 Billion CNY (≈ $10.00 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Jiangsu Hengrui Medicine Co Ltd for the company's overall valuation and market capitalisation.
Total Assets of Jiangsu Hengrui Medicine Co Ltd (1997–2024)
Total assets of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024. This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's total assets have evolved over time, based on quarterly financial data. See Jiangsu Hengrui Medicine Co Ltd (600276) stock price for real-time trading data and today's change.
Jiangsu Hengrui Medicine Co Ltd - Asset Composition Analysis
Jiangsu Hengrui Medicine Co Ltd Total Assets Breakdown (December 2024)
Jiangsu Hengrui Medicine Co Ltd total assets breakdown as of December 2024. Jiangsu Hengrui Medicine Co Ltd's total assets of CN¥68.33 Billion consist of 70.4% current assets and 29.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 49.5% |
| Accounts Receivable | CN¥6.23 Billion | 12.4% |
| Inventory | CN¥2.42 Billion | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥5.03 Billion | 10.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1997–2024)
This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Jiangsu Hengrui Medicine Co Ltd (600276) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Hengrui Medicine Co Ltd's current assets represent 70.4% of total assets in 2024, an increase from 53.8% in 1997.
- Cash Position: Cash and equivalents constituted 49.5% of total assets in 2024, up from 7.8% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 1.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 12.4% of total assets.
Jiangsu Hengrui Medicine Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Hengrui Medicine Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Jiangsu Hengrui Medicine Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.55 | 9.00 | 7.44 |
| Quick Ratio | 6.20 | 8.34 | 6.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥43.55 Billion | CN¥30.63 Billion | CN¥24.28 Billion |
Jiangsu Hengrui Medicine Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Hengrui Medicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.50 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 14.5% |
| Total Assets | CN¥50.14 Billion |
| Market Capitalization | $45.23 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Jiangsu Hengrui Medicine Co Ltd's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Jiangsu Hengrui Medicine Co Ltd's assets grew by 14.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jiangsu Hengrui Medicine Co Ltd (1997–2024)
The table below shows the annual total assets of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥50.14 Billion ≈ $7.34 Billion |
+14.51% |
| 2023-12-31 | CN¥43.78 Billion ≈ $6.41 Billion |
+3.38% |
| 2022-12-31 | CN¥42.36 Billion ≈ $6.20 Billion |
+7.87% |
| 2021-12-31 | CN¥39.27 Billion ≈ $5.75 Billion |
+13.06% |
| 2020-12-31 | CN¥34.73 Billion ≈ $5.08 Billion |
+26.03% |
| 2019-12-31 | CN¥27.56 Billion ≈ $4.03 Billion |
+23.23% |
| 2018-12-31 | CN¥22.36 Billion ≈ $3.27 Billion |
+23.96% |
| 2017-12-31 | CN¥18.04 Billion ≈ $2.64 Billion |
+25.88% |
| 2016-12-31 | CN¥14.33 Billion ≈ $2.10 Billion |
+24.64% |
| 2015-12-31 | CN¥11.50 Billion ≈ $1.68 Billion |
+26.52% |
| 2014-12-31 | CN¥9.09 Billion ≈ $1.33 Billion |
+25.85% |
| 2013-12-31 | CN¥7.22 Billion ≈ $1.06 Billion |
+22.53% |
| 2012-12-31 | CN¥5.89 Billion ≈ $862.26 Million |
+22.30% |
| 2011-12-31 | CN¥4.82 Billion ≈ $705.03 Million |
+23.68% |
| 2010-12-31 | CN¥3.90 Billion ≈ $570.05 Million |
+29.90% |
| 2009-12-31 | CN¥3.00 Billion ≈ $438.83 Million |
+33.03% |
| 2008-12-31 | CN¥2.25 Billion ≈ $329.88 Million |
+11.95% |
| 2007-12-31 | CN¥2.01 Billion ≈ $294.67 Million |
+38.12% |
| 2006-12-31 | CN¥1.46 Billion ≈ $213.35 Million |
+13.44% |
| 2005-12-31 | CN¥1.29 Billion ≈ $188.07 Million |
+2.38% |
| 2004-12-31 | CN¥1.26 Billion ≈ $183.70 Million |
-13.46% |
| 2003-12-31 | CN¥1.45 Billion ≈ $212.28 Million |
+20.43% |
| 2002-12-31 | CN¥1.20 Billion ≈ $176.27 Million |
+7.65% |
| 2001-12-31 | CN¥1.12 Billion ≈ $163.75 Million |
+13.46% |
| 2000-12-31 | CN¥986.27 Million ≈ $144.32 Million |
+112.69% |
| 1999-12-31 | CN¥463.71 Million ≈ $67.85 Million |
+26.86% |
| 1998-12-31 | CN¥365.52 Million ≈ $53.49 Million |
+26.52% |
| 1997-12-31 | CN¥288.92 Million ≈ $42.28 Million |
-- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more